id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-2595-0004,FDA,FDA-2018-E-2595,Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,Notice,Determinations,2019-11-29T05:00:00Z,2019,11,2019-11-29T05:00:00Z,2020-05-28T03:59:59Z,2019-11-29T19:13:51Z,2019-25850,0,0,09000064841c881f
FDA-2018-E-2595-0003,FDA,FDA-2018-E-2595,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:31:25Z,,0,0,0900006484116879